**Supplementary Table 4. Change in lung function for each one-point increase in FIB-4 score in men and women with MAFLD (*n*=519)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Unadjusted model 1** | ***p*** | **Adjusted model 2** | ***p*** | **Adjusted model 3** | ***p*** |
| MAFLD (men, *n*=299） |  |  |  |  |  |  |
| FVC, L | −0.594 (−0.881, −0.306) | <0.001 | −1.063(−1.725, −0.401) | 0.002 | −0.801 (−1.304, −0.329) | 0.004 |
| FVC, % of predicted value | −8.787 (−15.943, −1.631) | 0.016 | −4.201(−11.262, −2.861) | 0.243 | −12.502 (−23.011, 0.990) | 0.235 |
| FEV1, L | −0.501 (−0.766, −0.503) | <0.001 | −1.102(−1.673, −0.531) | 0.001 | −0.811 (−0.739, −0.140) | 0.016 |
| FEV1, % of predicted value | −9.689 (−17.084, −2.290) | 0.010 | −5.409(−7.083, 4.435) | 0.114 | −11.824 (−22.426, −0.280) | 0.280 |
| FEV1 /FVC, % | −0.828 (−5.485, 3.829) | 0.727 | 0.553(−4.085, 5.190) | 0.815 | −3.218 (−10.891, 4.455) | 0.409 |
| MAFLD (women, *n*=220） |  |  |  |  |  |  |
| FVC, L | −0.538 (−0.790, −0.285) | <0.001 | −0.351(−0.610, −0.093) | 0.008 | −0.180 (−0.452, −0.092) | 0.014 |
| FVC, % of predicted value | −6.884 (−9.827, −8.159) | 0.847 | −1.167(−9.362, −7.028) | 0.281 | −4.824 (−12.534, 1.316) | 0.107 |
| FEV1, L | −0.406 (−0.614, −0.199) | <0.001 | −0.206(−0.380, −0.042) | 0.015 | −0.122 (−0.332, −0.050) | 0.032 |
| FEV1, % of predicted value | −2.647 (−9.724, 1.646) | 0.548 | −1.342(−6.083, 5.425) | 0.668 | −6.053 (−15.621, 2.515) | 0.668 |
| FEV1 /FVC, % | 1.446 (−3.536, 6.512) | 0.560 | 1.912 (−2.578.961) | 0.534 | 0.968 (−7.066, 9.003) | 0.812 |

Data are beta coefficients (95% CI). Model 1: univariable linear regression analysis (unadjusted model); Model 2: adjusted for age ≥65 years, prior COPD, smoking status and significant alcohol intake; Model 3: adjusted for the same covariates of model 2 plusadiposity (BMI and waist circumference), blood pressure, WBC count, hemoglobin, serum transaminases, fasting glucose, and plasma lipid profile.